AMGN · Q1 2026 Earnings

Narrative arc: Q2 R&D-accelerate → Q3 outcome-data-validates → Q4 pipeline-carries-the-franchise → Q1 springboard-thesis-proven.

Three quarters ago Maritide was framed as four Phase III studies in obesity/diabetes/OSA. Two quarters ago that widened to six global studies adding CV and HF. Last quarter "stands alone as the only therapy in late-stage development to offer the paradigm-changing prospect of strong efficacy and favorable tolerability at monthly, every other month, or even quarterly dosing." This quarter management dropped "stands alone" and went further: "Maritide is emerging as a new paradigm for patients with obesity, diabetes, and related conditions as a well-tolerated, first monthly or less frequently administered medicine." "New paradigm" is category-defining language — management is now positioning Maritide not as a better entrant in the obesity category but as the redefinition of it. Two new Phase III maintenance studies and a switching-from-weekly-GLP-1 study were initiated this quarter, expanding the indication footprint.

Repatha's escalation continued its multi-quarter arc. Q2 framed Repatha at "40% of new-to-brand already primary prevention." Q3 added the Vesalius CV outcomes data. Q4 asserted guidelines should change because of Amgen's data. This quarter management closed the loop with declarative finality: "The body of evidence is now very clear. Treating patients earlier with [Repatha] can lower cardiovascular events." That "very clear" framing — coupled with sustained NBRx increases across cardiology and primary care — signals management believes the payer-friction battle is now post-inflection, not still being fought.

AI moved from talking point to quantified operational engine. Q3 cited the digital-twin manufacturing initiative in passing. This quarter management produced specific numbers: "Antibody lead optimization is accelerated by 50%... a proprietary site selection model that improves clinical trial enrollment with a significant and in some cases up to three-fold improvement in enrollment rates... AI-enabled automation has reduced production line clearance time at one of our manufacturing sites from approximately 30 minutes to about two minutes per batch run." This is the first quarter where AI productivity is presented as tangible R&D and manufacturing leverage rather than aspirational framing.

IMDELLTRA moved from 2L standard of care toward earlier-line evaluation. Q4 positioned IMDELLTRA as "standard of care with unprecedented survival." This quarter management cited a median OS of 25.3 months in the first-line setting from the Phase 1b DeLLphi-303 study; frontline maintenance is being formally evaluated in the ongoing Phase 3 DeLLphi-305 study, with DeLLphi-306 (post-chemoradiation, LS-SCLC) and DeLLphi-312 (1L ES-SCLC combination) rounding out the 1L Phase 3 program. Separately, management disclosed an FDA collaboration on a real-world prospective trial design pilot — distinct from the Phase 3 1L program — leveraging electronic health records and real-time data capture. That regulatory posture signals confidence in both the data and the agency relationship and is meaningful for the 2026 catalyst calendar.

The IRS NOPA disclosure deserves attention. Management hedged carefully — "If sustained in full, the adjustments set forth in the draft NOPA could have a material impact on our financial statements" — while asserting "We firmly believe that the IRS positions are without merit, and we also believe that our tax reserves are appropriate." This is a new disclosure layer covering 2016–2018, on top of the existing 2010–2015 litigation expecting a decision in H2 2026. Two contemporaneous IRS disputes spanning eight tax years is a tail risk that warrants tracking, though it sits outside the current EPS math.